

## Press Release

### Overseas Regulatory Announcement: Filing of Form F-3

**Hong Kong, Shanghai & Florham Park, NJ: Friday, June 28, 2024:** HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today filed the Form F-3 Registration Statement with the U.S. Securities and Exchange Commission. This filing follows the expiration of the previous Form F-3 Registration Statement filed in 2020. The Form F-3 is available for viewing at [http://www.rns-pdf.londonstockexchange.com/rns/3865U\\_1-2024-6-28.pdf](http://www.rns-pdf.londonstockexchange.com/rns/3865U_1-2024-6-28.pdf) and also on the website of the Company at [www.hutch-med.com](http://www.hutch-med.com).

#### About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S. For more information, please visit: [www.hutch-med.com](http://www.hutch-med.com) or follow us on [LinkedIn](#).

#### CONTACTS

**Investor Enquiries** +852 2121 8200 / [ir@hutch-med.com](mailto:ir@hutch-med.com)

#### Media Enquiries

Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / [HUTCHMED@fticonsulting.com](mailto:HUTCHMED@fticonsulting.com)  
Zhou Yi, Brunswick +852 9783 6894 (Mobile) / [HUTCHMED@brunswickgroup.com](mailto:HUTCHMED@brunswickgroup.com)

#### Nominated Advisor

Atholl Tweedie / Freddy Crossley / +44 (20) 7886 2500  
Rupert Dearden, Panmure Gordon